JY
VRDN icon

Jeff Yass’s Viridian Therapeutics VRDN Stock Holding History

Jeff Yass’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Sell
46,600
-127,500
-73% -$2.05M ﹤0.01% 8595
2026
Q1 		$3.41M Buy
174,100
+145,300
+505% +$4.32M ﹤0.01% 5012
2025
Q4 		$896K Buy
28,800
+19,000
+194% +$521K ﹤0.01% 7427
2025
Q3 		$211K Buy
+9,800
New +$177K ﹤0.01% 10877
2025
Q1 		– Sell
-74,600
Closed -$1.43M – 13545
2024
Q4 		$1.43M Buy
74,600
+300
+0.4% +$6.52K ﹤0.01% 6067
2024
Q3 		$1.69M Buy
74,300
+100
+0.1% +$1.64K ﹤0.01% 5627
2024
Q2 		$965K Sell
74,200
-9,100
-11% -$126K ﹤0.01% 6683
2024
Q1 		$1.46M Buy
83,300
+58,000
+229% +$1.12M ﹤0.01% 6073
2023
Q4 		$551K Buy
+25,300
New +$399K ﹤0.01% 8418
2023
Q3 		– Sell
-78,000
Closed -$1.86M – 13085
2023
Q2 		$1.86M Buy
78,000
+25,900
+50% +$664K ﹤0.01% 5303
2023
Q1 		$1.33M Buy
52,100
+7,300
+16% +$234K ﹤0.01% 6104
2022
Q4 		$1.31M Buy
44,800
+2,100
+5% +$48.4K ﹤0.01% 5594
2022
Q3 		$876K Buy
42,700
+10,900
+34% +$196K ﹤0.01% 6982
2022
Q2 		$368K Sell
31,800
-7,100
-18% -$95.4K ﹤0.01% 9001
2022
Q1 		$719K Buy
38,900
+11,200
+40% +$215K ﹤0.01% 8011
2021
Q4 		$548K Buy
27,700
+10,500
+61% +$196K ﹤0.01% 8943
2021
Q3 		$283K Buy
+17,200
New +$252K ﹤0.01% 10733

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jeff Yass's VRDN Position: Q2 2026 in Review

Jeff Yass increased its Viridian Therapeutics (VRDN) stake by 140% in Q2 2026, buying an estimated $1.22M and bringing the position to 130,284 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

Jeff Yass first reported a position in VRDN in Q1 2015 and has held it in 23 quarters since. The position peaked at $5M in Q2 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Jeff Yass held 130,284 shares of Viridian Therapeutics worth $2.39M as of Q2 2026.
  • Jeff Yass bought 76,007 Viridian Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Viridian Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6079 holding.
  • Jeff Yass first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Jeff Yass's Viridian Therapeutics position peaked at $5M in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.